Clinical Indications targeted by the SonoProbe
Given the neurosurgical specialty of Pr. Carpentier, the SonoProbe was designed to be used for the treatment of a range of indications in the brain: tumors, epileptic lesions, radiosurgery resistant metastases, meningiomas … with a net annual incidence in Europe and in the United States of more than 400,000 patients.
Due to its design, the SonoProbe can also be adapted for the treatment of diseases in other organs. It potentially can also be used for treatments in moving organs or in organs hidden by bony structures (liver, lung …)
Below, the two main stages of treatment of a brain tumor by the SonoProbe are described.
The SonoProbe treatment
The first step is diagnostic. It begins with local anesthesia and stereotactic insertion of the probe within the tumor. A biopsy is performed to determine the precise histological status of the tumor. In the same step, still under local anesthesia, the treatment can take place.
The second step is therapeutic. It happens within the MRI scanner. After verification by MRI of the exact positioning of the probe relative to the tumor, treatment planning is performed. The treatment can then begin, with continuous monitoring using MR images acquired in real-time. The treatment itself lasts between 5 and 15 minutes. At the end of the procedure, the patient is discharged from the MRI, the probe is removed, and the patient is able to leave the hospital (the same day).